<?xml version="1.0" encoding="UTF-8"?>
<p>Following a screening period of 30 days, eligible patients were sequentially assigned to receive SC injections of one of three weight‐based doses of Rolontis (45, 135, or 270 
 <italic>μ</italic>g/kg) or a fixed dose of 6 mg of pegfilgrastim. On Day 1 of each cycle, patients were treated with docetaxel (75 mg/m
 <sup>2</sup>) and cyclophosphamide (600 mg/m
 <sup>2</sup>) by IV infusion every 3 weeks for up to four cycles. On Day 2 of each cycle (approximately 24 h after TC chemotherapy), patients administered their assigned study treatment with either Rolontis or pegfilgrastim.
</p>
